Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01665352 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes
A Phase 2 study of Type 2 Diabetes Mellitus, sponsored by vTv Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 186
- Enrollment target
- 19
- Study locations
NCT01665352: Completed Phase 2 study of Type 2 Diabetes Mellitus, sponsored by vTv Therapeutics.
NCT01665352 is a Phase 2 study of Type 2 Diabetes Mellitus that has completed, run by vTv Therapeutics. The registered enrollment target is 186 participants, below the 2,958-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (94% lower). The trial reports 19 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01665352, a Phase 2 study of Type 2 Diabetes Mellitus, has completed, sponsored by vTv Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 186 participants
- Enrollment target
- 19
- Study locations
Study Summary
The purpose of this study is to compare the safety and effect of TTP054 versus placebo on glucose control in patients with type 2 diabetes.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG TTP054
Study Locations (19)
Texas
- Site 16 - Dallas
- Site 10 - Houston
- Site 2 - Houston
- Site 11 - Katy
California
- Site 18 - Chula Vista
- Site 1 - Los Angeles
Florida
- Site 4 - Coral Gables
- Site 5 - Port Orange
Colorado
- Site 13 - Denver
Hawaii
- Site 3 - Honolulu
Indiana
- Site 17 - Indianapolis
Kentucky
- Site 7 - Louisville
Maine
- Site 8 - Auburn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 186 participants |
| Start Date | 2012-08 |
| Est. Completion | 2013-05 |
| Phase | Phase 2 |
What the finished NCT01665352 record still lists
NCT01665352 is an interventional study that assigns participants to a tested intervention. The registered 186 participants enrollment target is mid-sized for trials with a published cap, below the 2,958-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01665352 lists 19 locations in 14 states (Texas, California, Florida).
Frequently Asked Questions
What is clinical trial NCT01665352 about?
NCT01665352 is a clinical study titled "A Study to Evaluate Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes". The purpose of this study is to compare the safety and effect of TTP054 versus placebo on glucose control in patients with type 2 diabetes.
What is the current status of trial NCT01665352?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 186 participants. The study started on 2012-08. Estimated completion is 2013-05.
What conditions does trial NCT01665352 study?
This clinical trial studies the following conditions: Type 2 Diabetes Mellitus.
What interventions are being tested in trial NCT01665352?
The interventions under investigation include: Placebo (DRUG), TTP054 (DRUG).
Who is sponsoring clinical trial NCT01665352?
This trial is sponsored by vTv Therapeutics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01665352 being conducted?
This trial has 19 study locations across California, Colorado, Florida, Hawaii, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01665352's enrollment target sits among peer trials
186 40th of 130 higher than 91 of 130 other Type 2 Diabetes Mellitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes
RECRUITING · Phase 2
-
Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
RECRUITING · Phase 2
-
Regulation of Endogenous Glucose Production by Central KATP Channels
RECRUITING · Phase 2
-
Signaling Mechanisms and Vascular Function in Patients With Diabetes Mellitus
COMPLETED · Phase 2
-
The Effect of Bariatric Surgery on Metabolism, the Metabolome and Microbiome in Patients With Type 2 Diabetes
COMPLETED · Phase 2
-
Study to Assess the Effects of FX006 on Blood Glucose in Patients With OA of the Knee and Type 2 Diabetes
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03567889 · 186 participants · Phase 3
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
- NCT05281471 · 186 participants · Phase 3
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- NCT05405595 · 186 participants · Phase 1
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
- NCT05762107 · 186 participants · Phase 2
A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia